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Mechanical Circulatory Support
We Are Halfway There*
Salpy V. Pamboukian, MD, MSPH
Birmingham, Alabama
The role of mechanical circulatory device therapy has
progressed rapidly over the last 2 decades, from supporting
the failing heart in hospitalized patients awaiting heart
transplantation to permanent or “destination” outpatient
therapy in individuals with end-stage systolic heart failure
(HF) for whom transplantation is not an option. Over this
period, devices themselves have evolved through several
generations. First-generation pulsatile devices have given
way to second- and third-generation continuous flow ven-
tricular assist devices (VADs), on the basis of axial and
centrifugal flow, respectively. In this issue of the Journal,
trueber et al. (1) report their experience with the HeartWare
entricular Assist System (HeartWare, Inc., Framingham,
assachusetts) as a bridge to cardiac transplantation in a
ulticenter prospective nonrandomized single-arm clinical
rial. In this cohort of 50 patients, survival to heart trans-
lantation, myocardial recovery and explant, or ongoing
upport at 6, 12, and 24 months was 90%, 84%, and 79%,
espectively.
See page 1375
Over this evolutionary period, 6 major hurdles can be
identified that have limited the widespread application of
this technology. These include: 1) device size; 2) device
durability; 3) survival; 4) driveline infections; 5) thrombotic
and bleeding complications; and 6) awareness of the benefits
of this technology in the greater cardiology community and
timely referral.
Device size. Earlier iterations of fully implantable VADs,
such as the HeartMate XVE (Thoratec Corporation, Pleas-
anton, California), were large and required the patients to
have the anatomical space to accept the pump, generally a
body surface area of 1.5 m2. With the advent of the axial
ow HeartMate II (Thoratec Corporation), much smaller
atients could physically accommodate the pump, which
tself weighs only 290 g. The HeartWare device, weighing
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Dr. Pamboukian has received honoraria from Thoratec.40 g with a diameter of 53 mm, has the advantage of an
ntegrated inflow cannula situated directly in the left ven-
ricle with the pump placement in the pericardium, elimi-
ating the need for entry into the abdominal space. Now a
ide range of patients of varying sizes, including larger
hildren and smaller adults, can benefit from VAD therapy.
urability. A major limitation of first-generation devices
as durability. Incidence of device failure of HeartMate
VE (Thoratec Corporation) was on the order of 31% to
5% at 24 months, largely due to internal bearing wear and
egradation of the valved inflow cannula (2,3). This issue
as essentially been resolved with newer-generation devices.
onger-term experience with the HeartMate II (Thoratec
orporation) in a bridge-to-transplant cohort demonstrated
o instances of primary mechanical pump failure in patients
till receiving support at 18 months (4). In a comparison of
he continuous flow HeartMate II with the pulsatile Heart-
ate XVE (Thoratec Corporation) in a destination therapy
ohort, the need for device repair or replacement strongly
avored the continuous-flow device: 10% versus 36% (p 
.001) at 2 years (5). In the early experience with the
eartWare device presented by Strueber et al. (1), only 7
atients (14%) underwent device replacement, 2 for a
anufacturing issue that was resolved without sequela.
urvival. The role of VAD therapy as a bridge to cardiac
ransplantation has been well-established since the early
990s. Recently published studies have shown the benefit of
ewer VAD designs for this indication (6). It was the
andmark REMATCH (Randomized Evaluation of Me-
hanical Assistance for the Treatment of Congestive Heart
ailure) trial, published in 2001, that first established VADs
s a permanent therapy for patients not suitable for heart
ransplantation. This study randomized 129 New York
eart Association functional class IV patients with end-
tage HF who were ineligible for heart transplant to therapy
ith the HeartMate VE (Thoratec Corporation) left ven-
ricular assist device (LVAD) versus ongoing “optimal
edical management.” At the end of 12 months, survival
as 52% in the LVAD-treated group versus 25% in the
edically treated arm. At 2 years, survival was 23% versus
%, respectively (3). The results of this study led to U.S. Food
nd Drug Administration approval of the HeartMate VE (and
ubsequently the HeartMate XVE) (Thoratec Corporation)
or destination therapy. Although this was a great leap forward
n the treatment of end-stage HF patients, many clinicians
utside the VAD community were unconvinced of the long-
erm benefits of this therapy, given poor 2-year outcomes,
espite further published data showing survival improvements
n the post-REMATCH era (7,8). It was not until publication
n 2009 of the results of the HeartMate II (Thoratec Corpo-
ation) destination therapy trial that a wider audience came to
ee the improvements in survival with second-generation axial
ow devices (5). Further “real-world” experience from the
NTERMACS (Inter-Agency Registry for Mechanically As-
isted Circulatory Support) registry has shown that 1-year
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80% (9). One can now confidently say that overall survival is
improved with VAD therapy, compared with the estimated
survival of HF patients.
Driveline-related infections. The incidence of LVAD
pocket infections has improved with smaller continuous-
flow VADs. The HeartWare VAD does not even require
the creation of a pump pocket, because of its intrapericardial
placement. However, the Achilles’ heel of VAD therapy
might well be driveline infection. The percutaneous driveline that
connects the internal pump to the external system controller
and power source is tunneled through the abdominal wall.
The disruption of the skin at the exit site represents a portal
for infection and poses a lifetime risk to the patient. Despite
significant improvements in many aspects of the care of
VAD patients, the incidence of driveline infection remains
high: 0.37 to 0.48 events/patient-year (5,6). Once a driv-
eline infection develops, it might be difficult to cure even
with prolonged antibiotic therapy and surgical intervention
(10). Either complete eradication of the driveline by trans-
cutaneous power transfer technology or improvements in
current driveline design and/or materials will be necessary to
eliminate this significant long-term risk to VAD patients.
Bleeding and thrombotic complications. Concerns for
thromboembolic events, especially stroke, exist with VAD
therapy. One advantage of the pulsatile HeartMate XVE
(Thoratec Corporation) was the fact that it did not require
systemic anticoagulation with warfarin. Stroke rates were on
the order of 0.19 events/patient-year (11). Newer-generation
continuous-flow pumps require anticoagulation therapy
with warfarin, generally with an international normalized
ratio of 2 to 3, although there are data suggesting that lower
international normalized ratio targets are appropriate in
patients with the HeartMate II (Thoratec Corporation)
(12). Antiplatelet therapy with aspirin, dipyridamole,
and/or clopidogrel is also used. Ischemic stroke rates with
second-generation VADs are on the order of 0.06 to 0.13
events/patient-year (5,6). Although stroke rates are lower,
new concerns about increased bleeding risk with
continuous-flow circulation due to acquired von Willebrand
factor are emerging (13). As the horizon of support with
these devices increases on the order of years, further expe-
rience and data will emerge on the long-term consequences
of pump–blood component interaction and nonpulsatile
perfusion on bleeding and clotting risk.
Acceptance and adoption of VAD therapy. Approxi-
mately 5 million Americans have HF, with National Hos-
pital Discharge Survey data from 1979 to 2004 indicating
that the number of hospital stays with any mention of HF
tripled from 1,274,000 in 1979 to 3,860,000 in 2004
(14,15). Heart transplantation rates have remained static, in
part due to limited donor organ supply. In 2008, approxi-
mately 2,000 heart transplants were performed (16). It
would seem that the chasm between the numbers in need of
advanced HF therapy and the limited donor supply could be
filled with the use of VAD therapy. Although numbers ofVADs implanted/year are increasing, it is still a relatively
rare treatment in the spectrum of HF therapy. From March
2006 to June 2010, 2,933 VAD implants were reported to
INTERMACS, a national registry for patients who are
receiving U.S. Food and Drug Administration-approved
mechanical circulatory support device therapy to treat ad-
vanced HF. Patients participating in clinical trials are
excluded from this registry; however, if it is estimated that
this group comprised an additional 500 to 1,000 patients in
the U.S., the total number of VAD implants is still small
compared with the potential pool of patients who could
benefit. There may be many reasons for this gap, but more
than likely it includes a lack of awareness of the therapy
itself in the greater medical community as opposed to poor
acceptance of the concept of mechanical circulatory support
by patients. Angiotensin-converting enzyme inhibitors, an-
giotensin receptor blockers, and beta-blockers—the benefits
of which were well-established in HF trials—took years to
be incorporated into the armamentarium of therapies of
many physicians and are still not prescribed to all who might
benefit (17). Ventricular assist device therapy, being an
exponentially more specialized and dramatic intervention,
will likely face substantial barriers to widespread adoption,
compared with challenges of acceptance of pharmacological
therapies.
With current VAD technology, including devices such as
the HeartWare, hurdles 1, 2, and 3 have been overcome to
a significant degree. However, the remaining 3 continue to
present significant challenges to clinicians who manage
patients with mechanical circulatory support device therapy.
Hurdles 4 and 5 will likely be surmounted as technology and
medical management evolves. The final hurdle might be the
most difficult to conquer. Dissemination of scientific data
showing benefits of VAD therapy is critical. However, the
most powerful tool might be the patients themselves. As
more patients receive VADs and return to their communi-
ties with improved quality of life, they will serve as ambas-
sadors for this lifesaving therapy.
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